1441. Doses of 13-Valent Conjugated Pneumococcal Vaccine (PCV13) for Patients With Multiple Myeloma (MM)

Abstract

Background. Patients with MM are vulnerable to bacterial infection, especially invasive pneumococcal diseases. Vaccination with one-dose PCV13 is recommended, but their poor immunogenicity was observed. We aimed to assess whether two-dose PCV13 might help. Methods. Patients with MM were randomized to receive one- or two- dose PCV13. The two doses were given 1 month apart. Measurements of antibody to the four most common serotypes 6B, 14, 19F, and 23F pre-vaccination, 1, 3, 6, 9, and 12 months after the last dose of PCV13 were performed. Achievement of significant antibody response was defined as greater than equal to twofold increase in the IgG level. Results. From January 2016 to December 2017, a total of 72 patients were randomized to receive one (n = 35) or two doses (n = 37) PCV13. Of all, 31 patients (43%), including one dose in 14 and two doses in 17, had completed 12-month follow-up with a median age of 62 years old (IQR 54-66). Sequential changes of significant antibody responses to serotype 6B, 14, 19F, and 23F during 1-year follow-up in one and two does groups are presented in Figure 1. The proportions of significant antibody responses to serotype 6B, 14, 19F, and 23F after 1-year follow-up were 33.3, 25.0, 41.7, and 41.7% in one dose group and 11.8, 35.3, 29.4, and 23.5% in two-dose group, respectively. Conclusion. Two-dose PCV13 did not provide better immunogenicity to patients with MM. Innovative strategies to improve the immunogenicity of PCV13 in patients with MM are needed.